|
|
Article: Weight Loss With Qnexa Stops Progression Toward Type 2 Diabetes in Obese Non-Diabetic Patients.
- Article from:
- PR Newswire
- Article date:
- June 7, 2009
CopyrightCOPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Glycemic Data from Phase 3 EQUATE (OB-301) Study Results Presented at ADA Annual Meeting
NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- VIVUS, Inc. , a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health, today reported the glycemic findings from EQUATE (OB-301), a phase 3 trial evaluating Qnexa(TM) in non-diabetic, obese patients. After 28 weeks of treatment, blood sugar levels, as measured by hemoglobin A1c (HbA1c), were lower in the patients treated with Qnexa, while the patients in the placebo group had a significant increase in their HbA1c levels (p
Dr. Aronne stated, ...